Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)
This study has been terminated.
( Sponsor's decision )
Study NCT01587144   Information provided by Spectrum Pharmaceuticals, Inc

First Received on April 11, 2012.   Last Updated on April 1, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Glioblastoma Multiforme
Additional conditions recognized in this trial
Glioblastoma
More general conditions related to this trial
Astrocytoma
Glioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Interventions listed in this trial
Lucanthone
Temozolomide (TMZ)
Radiation
Placebo
Additional drug interventions recognized in this trial
Temozolomide
More general drug interventions related to this trial
Alkylating Agents
Anthelmintics
Anti-Infective Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antiparasitic Agents
Antiplatyhelmintic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Schistosomicides
Therapeutic Uses
Sponsors listed in this trial
Spectrum Pharmaceuticals, Inc


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services